Marshall Wace LLP Has $11.49 Million Stake in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Marshall Wace LLP increased its holdings in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 44.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,099,692 shares of the medical technology company’s stock after acquiring an additional 339,832 shares during the quarter. Marshall Wace LLP’s holdings in Alphatec were worth $11,492,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in ATEC. Van ECK Associates Corp boosted its position in Alphatec by 11.8% during the second quarter. Van ECK Associates Corp now owns 12,275 shares of the medical technology company’s stock worth $128,000 after purchasing an additional 1,300 shares during the period. ProShare Advisors LLC lifted its stake in shares of Alphatec by 8.5% during the 1st quarter. ProShare Advisors LLC now owns 16,572 shares of the medical technology company’s stock worth $229,000 after buying an additional 1,304 shares during the last quarter. Bayesian Capital Management LP boosted its holdings in shares of Alphatec by 5.6% during the 1st quarter. Bayesian Capital Management LP now owns 27,000 shares of the medical technology company’s stock worth $372,000 after buying an additional 1,442 shares during the period. Cetera Advisors LLC grew its stake in Alphatec by 15.6% in the 1st quarter. Cetera Advisors LLC now owns 12,720 shares of the medical technology company’s stock valued at $175,000 after buying an additional 1,720 shares during the last quarter. Finally, Bridgefront Capital LLC grew its stake in Alphatec by 10.3% in the 4th quarter. Bridgefront Capital LLC now owns 22,846 shares of the medical technology company’s stock valued at $345,000 after buying an additional 2,128 shares during the last quarter. Institutional investors own 66.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ATEC. Barclays initiated coverage on Alphatec in a report on Monday, July 8th. They set an “overweight” rating and a $19.00 price objective for the company. Stifel Nicolaus decreased their price objective on Alphatec from $19.00 to $16.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. Piper Sandler lowered their price objective on Alphatec from $17.00 to $12.00 and set an “overweight” rating on the stock in a research report on Thursday, August 1st. Wells Fargo & Company reduced their target price on shares of Alphatec from $26.00 to $19.00 and set an “overweight” rating for the company in a research report on Thursday, August 1st. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $20.00 price target on shares of Alphatec in a research report on Friday, August 30th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company. According to MarketBeat, Alphatec has an average rating of “Moderate Buy” and an average target price of $17.50.

Insider Activity at Alphatec

In other Alphatec news, Director David M. Demski bought 50,000 shares of the stock in a transaction on Wednesday, August 21st. The stock was purchased at an average price of $5.67 per share, with a total value of $283,500.00. Following the completion of the purchase, the director now owns 288,441 shares in the company, valued at $1,635,460.47. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 22.80% of the stock is currently owned by insiders.

Alphatec Price Performance

ATEC stock opened at $5.56 on Friday. The company’s 50-day moving average price is $6.82 and its two-hundred day moving average price is $10.03. The firm has a market cap of $777.76 million, a P/E ratio of -3.73 and a beta of 1.40. The company has a quick ratio of 1.21, a current ratio of 2.22 and a debt-to-equity ratio of 30.21. Alphatec Holdings, Inc. has a 12 month low of $5.28 and a 12 month high of $17.34.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings data on Wednesday, July 31st. The medical technology company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.03). The firm had revenue of $145.57 million for the quarter, compared to analyst estimates of $144.55 million. Alphatec had a negative net margin of 33.48% and a negative return on equity of 816.57%. The firm’s revenue for the quarter was up 24.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.43) earnings per share. On average, analysts anticipate that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.